AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
WEDGE, Stephen R, KENDREW, Jane, CHESTER, Rosemary, JACKSON, Janet A, BOFFEY, Sarah J, KILBURN, Lyndsey L, BARNETT, Sharon, RICHMOND, Graham H. P, WADSWORTH, Peter F, WALKER, Mike, BIGLEY, Alison L, TAYLOR, Sian T, HENNEQUIN, Laurent F, COOPER, Lee, BECK, Sarah, JÜRGENSMEIER, Juliane M, OGILVIE, Donald J, VALENTINE, Paula J, BARRY, Simon T, BRAVE, Sandra R, SMITH, Neil R, JAMES, Neil H, DUKES, Michael, CURWEN, Jon O
Published in Cancer research (Chicago, Ill.) (15.05.2005)
Published in Cancer research (Chicago, Ill.) (15.05.2005)
Get full text
Journal Article
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
WEDGE, Stephen R, OGILVIE, Donald J, GRAHAM, George A, HUGHES, Gareth D, THOMAS, Andrew P, STOKES, Elaine S. E, CURRY, Brenda, RICHMOND, Graham H. P, WADSWORTH, Peter F, BIGLEY, Alison L, HENNEQUIN, Laurent F, DUKES, Michael, KENDREW, Jane, CHESTER, Rosemary, JACKSON, Janet A, BOFFEY, Sarah J, VALENTINE, Paula J, CURWEN, Jon O, MUSGROVE, Helen L
Published in Cancer research (Chicago, Ill.) (15.08.2002)
Get full text
Published in Cancer research (Chicago, Ill.) (15.08.2002)
Journal Article